Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAKHZYRO prophylaxis in Chinese hereditary angioedema patients
CTR20220819Phase 3Completed
- Sponsor
- Dyax Corp.
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of lanadelumab in hereditary angioedema (HAE), sponsored by Dyax Corp.. Started Apr 2022; status: completed.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on CTR20220819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220819.